Cargando…

Post hysteroscopic progesterone hormone therapy in the treatment of endometrial polyps

OBJECTIVE: To find out the clinical effects of post hysteroscopic progesterone hormone therapy in the treatment of endometrial polyps in terms of clinical outcome and the expression of endometrial Vascular Endothelial Growth Factor (VEGF). METHODS: Ninety-eight patients who were confirmed as endomet...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fangfang, Wei, Shuangyan, Yang, Shuye, Liu, Zhiqiang, Nan, Fangfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Professional Medical Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191810/
https://www.ncbi.nlm.nih.gov/pubmed/30344589
http://dx.doi.org/10.12669/pjms.345.15330
_version_ 1783363788485951488
author Li, Fangfang
Wei, Shuangyan
Yang, Shuye
Liu, Zhiqiang
Nan, Fangfang
author_facet Li, Fangfang
Wei, Shuangyan
Yang, Shuye
Liu, Zhiqiang
Nan, Fangfang
author_sort Li, Fangfang
collection PubMed
description OBJECTIVE: To find out the clinical effects of post hysteroscopic progesterone hormone therapy in the treatment of endometrial polyps in terms of clinical outcome and the expression of endometrial Vascular Endothelial Growth Factor (VEGF). METHODS: Ninety-eight patients who were confirmed as endometrial polyp in the hospital from April 2014 and December 2016 were selected and divided into treatment group and a control group using random number table, 49 in each group. Patients in both groups were given hysteroscopic operation. Patients in the treatment group were treated by progesterone hormone drugs after hysteroscopic operation, while patients in the control group were not given progesterone hormone. The changes of menstrual blood volume, menstrual cycle and expression of VEGF were compared between the two groups after treatment, and the recurrence condition, thickness of endometrium and hemoglobin were followed up one year after treatment. RESULTS: The pictorial blood loss assessment chart (PBAC) scores of patients in the two groups had no significant difference before treatment (P>0.05); but the score of the treatment group was much lower than that of the control group. The improvement rate of menstrual cycle of the treatment group was much higher than that of the control group, and the difference had statistical significance (P<0.05). Compared to before treatment, the serum VEGF level of the patients in both groups had a remarkable decline in the 1(st), 3(rd) and 6(th) month after treatment, and the difference had statistical significance (P<0.05). The difference of the serum VEGF level between the two groups in the 1(st) and 3(rd) month after treatment had no statistical significance (P>0.05). The serum VEGF level of the treatment group was notably lower than that of the control group six months after treatment, and the difference had statistical significance (P<0.05). The follow-up results demonstrated that the treatment group had smaller thickness of endometrium and higher level of hemoglobin compared to the control group, and the recurrence rate of the treatment group was lower than that of the control group (P<0.05). CONCLUSION: Post hysteroscopic progesterone hormone therapy has favorable clinical effect in treating endometrial polyps as it can effectively prevent the recurrence of endometrial polyps, relieve the level of hemoglobin and reduce endometrial thickness.
format Online
Article
Text
id pubmed-6191810
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Professional Medical Publications
record_format MEDLINE/PubMed
spelling pubmed-61918102018-10-19 Post hysteroscopic progesterone hormone therapy in the treatment of endometrial polyps Li, Fangfang Wei, Shuangyan Yang, Shuye Liu, Zhiqiang Nan, Fangfang Pak J Med Sci Original Article OBJECTIVE: To find out the clinical effects of post hysteroscopic progesterone hormone therapy in the treatment of endometrial polyps in terms of clinical outcome and the expression of endometrial Vascular Endothelial Growth Factor (VEGF). METHODS: Ninety-eight patients who were confirmed as endometrial polyp in the hospital from April 2014 and December 2016 were selected and divided into treatment group and a control group using random number table, 49 in each group. Patients in both groups were given hysteroscopic operation. Patients in the treatment group were treated by progesterone hormone drugs after hysteroscopic operation, while patients in the control group were not given progesterone hormone. The changes of menstrual blood volume, menstrual cycle and expression of VEGF were compared between the two groups after treatment, and the recurrence condition, thickness of endometrium and hemoglobin were followed up one year after treatment. RESULTS: The pictorial blood loss assessment chart (PBAC) scores of patients in the two groups had no significant difference before treatment (P>0.05); but the score of the treatment group was much lower than that of the control group. The improvement rate of menstrual cycle of the treatment group was much higher than that of the control group, and the difference had statistical significance (P<0.05). Compared to before treatment, the serum VEGF level of the patients in both groups had a remarkable decline in the 1(st), 3(rd) and 6(th) month after treatment, and the difference had statistical significance (P<0.05). The difference of the serum VEGF level between the two groups in the 1(st) and 3(rd) month after treatment had no statistical significance (P>0.05). The serum VEGF level of the treatment group was notably lower than that of the control group six months after treatment, and the difference had statistical significance (P<0.05). The follow-up results demonstrated that the treatment group had smaller thickness of endometrium and higher level of hemoglobin compared to the control group, and the recurrence rate of the treatment group was lower than that of the control group (P<0.05). CONCLUSION: Post hysteroscopic progesterone hormone therapy has favorable clinical effect in treating endometrial polyps as it can effectively prevent the recurrence of endometrial polyps, relieve the level of hemoglobin and reduce endometrial thickness. Professional Medical Publications 2018 /pmc/articles/PMC6191810/ /pubmed/30344589 http://dx.doi.org/10.12669/pjms.345.15330 Text en Copyright: © Pakistan Journal of Medical Sciences http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Li, Fangfang
Wei, Shuangyan
Yang, Shuye
Liu, Zhiqiang
Nan, Fangfang
Post hysteroscopic progesterone hormone therapy in the treatment of endometrial polyps
title Post hysteroscopic progesterone hormone therapy in the treatment of endometrial polyps
title_full Post hysteroscopic progesterone hormone therapy in the treatment of endometrial polyps
title_fullStr Post hysteroscopic progesterone hormone therapy in the treatment of endometrial polyps
title_full_unstemmed Post hysteroscopic progesterone hormone therapy in the treatment of endometrial polyps
title_short Post hysteroscopic progesterone hormone therapy in the treatment of endometrial polyps
title_sort post hysteroscopic progesterone hormone therapy in the treatment of endometrial polyps
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191810/
https://www.ncbi.nlm.nih.gov/pubmed/30344589
http://dx.doi.org/10.12669/pjms.345.15330
work_keys_str_mv AT lifangfang posthysteroscopicprogesteronehormonetherapyinthetreatmentofendometrialpolyps
AT weishuangyan posthysteroscopicprogesteronehormonetherapyinthetreatmentofendometrialpolyps
AT yangshuye posthysteroscopicprogesteronehormonetherapyinthetreatmentofendometrialpolyps
AT liuzhiqiang posthysteroscopicprogesteronehormonetherapyinthetreatmentofendometrialpolyps
AT nanfangfang posthysteroscopicprogesteronehormonetherapyinthetreatmentofendometrialpolyps